130 related articles for article (PubMed ID: 30033421)
1. Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
Ahmad L; Iqbal Z; Shah Y; Nazir S; Khan A; Khan MI; Khan A; Khuda F; Khan I
Pak J Pharm Sci; 2018 Jul; 31(4):1363-1374. PubMed ID: 30033421
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle.
Nazir S; Iqbal Z; Ahmad L; Shah Y; Nasir F
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):13-22. PubMed ID: 24390778
[TBL] [Abstract][Full Text] [Related]
3. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Fan L; Wang G; Wang LS; Chen Y; Zhang W; Huang YF; Huang RX; Hu DL; Wang D; Zhou HH
Acta Pharmacol Sin; 2007 Oct; 28(10):1685-92. PubMed ID: 17883958
[TBL] [Abstract][Full Text] [Related]
4. Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
Nazir S; Iqbal Z; Ahmad L; Ahmad S
Pak J Pharm Sci; 2016 May; 29(3):887-94. PubMed ID: 27166533
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Lawson EB; Wu JC; Baldwin RM; Ingelman-Sundberg M; Rosenborg S; Yim DS; Yin OQ; Capparelli EV; Ma JD
Eur J Clin Pharmacol; 2012 Apr; 68(4):407-13. PubMed ID: 22009190
[TBL] [Abstract][Full Text] [Related]
6. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
7. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.
Park S; Hyun YJ; Kim YR; Lee JH; Ryu S; Kim JM; Oh WY; Na HS; Lee JG; Seo DW; Hwang IY; Park Z; Jang IJ; Oh J; Choi SE
J Korean Med Sci; 2017 May; 32(5):729-736. PubMed ID: 28378544
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.
Na JY; Jeon I; Yoon J; Choi Y; Yoon SH; Yu KS; Chung JY
Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1469-1477. PubMed ID: 34337876
[TBL] [Abstract][Full Text] [Related]
10. Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children.
Favela-Mendoza AF; Martínez-Cortes G; Romero-Prado MM; Romero-Tejeda EM; Islas-Carbajal MC; Sosa-Macias M; Lares-Asseff I; Rangel-Villalobos H
J Clin Pharm Ther; 2018 Oct; 43(5):656-663. PubMed ID: 29733119
[TBL] [Abstract][Full Text] [Related]
11. Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers.
Ahmad L; Iqbal Z; Nazir S; Khan A; Shah Y; Khan MI; Khan I; Khan A
EXCLI J; 2017; 16():321-327. PubMed ID: 28507476
[TBL] [Abstract][Full Text] [Related]
12. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.
Payan M; Rouini MR; Tajik N; Ghahremani MH; Tahvilian R
Daru; 2014 Dec; 22(1):81. PubMed ID: 25498969
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.
Tu JH; Hu DL; Dai LL; Sun Y; Fan L; Zhang M; Tan ZR; Chen Y; Li Z; Zhou HH
Xenobiotica; 2010 Jun; 40(6):393-9. PubMed ID: 20350051
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults.
Lin S; Nikanjam M; Capparelli EV; Allegrini A; Pavone D; Yim DS; Hammami MM; Bertino JS; Nafziger AN; Park YS; Kang JS; Yin OQ; Ma JD
Ther Drug Monit; 2018 Dec; 40(6):754-758. PubMed ID: 30045358
[TBL] [Abstract][Full Text] [Related]
16. Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations.
Shilbayeh S; Tutunji MF
Clin Pharmacokinet; 2006; 45(6):593-610. PubMed ID: 16719541
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.
Zhou S; Xie R; Zhang X; He X; Huang J; Jungang Y; Liao M; Ding Y; Yang D; Liu Y; Zhang Q; Yang G; Liu F; Guan S; He Q; Lou H; Gong F; Meng X; Xiang Q; Zhao X; Cui Y
Clin Transl Sci; 2022 Jun; 15(6):1439-1448. PubMed ID: 35235711
[TBL] [Abstract][Full Text] [Related]
18. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Ohnishi A; Murakami S; Akizuki S; Mochizuki J; Echizen H; Takagi I
J Clin Pharmacol; 2005 Nov; 45(11):1221-9. PubMed ID: 16239354
[TBL] [Abstract][Full Text] [Related]
19. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.
Kearns GL; Leeder JS; Gaedigk A
Drug Metab Dispos; 2010 Jun; 38(6):894-7. PubMed ID: 20223877
[TBL] [Abstract][Full Text] [Related]
20. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
Baldwin RM; Ohlsson S; Pedersen RS; Mwinyi J; Ingelman-Sundberg M; Eliasson E; Bertilsson L
Br J Clin Pharmacol; 2008 May; 65(5):767-74. PubMed ID: 18294333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
